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SUMMARY
Although responsive neurostimulation (RNS) is approved for treatment of resistant
focal epilepsy in adults, little is known about response to treatment of specific corti-
cal targets. We describe the experience of RNS targeting the insular lobe. We iden-
tified patients who had RNS implantation with at least one electrode within the
insula between April 2014 and October 2015. We performed a retrospective review
of preoperative clinical features, imaging, electrocardiogram (EEG), intraoperative
electrocorticography (ECoG), and postoperative seizure outcome. Eight patients
with at least 6 months of postimplant follow-up were identified. Ictal localization
was inconclusive with MRI or scalp EEG findings. Intracranial EEG monitoring or
intraoperative ECoG demonstrated clear ictal onsets and/or frequent interictal
discharges in the insula. Four patients demonstrated overall 50–75% reduction in
seizure frequency. Two patients did not show appreciable seizure improvement.
One patient has experienced a 75% reduction of seizure frequency, and another is
nearly seizure free postoperatively. There were no reported direct complications of
insular RNS electrode placement or stimulation, though two patients had postopera-
tive complications thought to be related to craniotomy (hydrocephalus and late
infection). Our study suggests that insular RNS electrode placement in selected
patients is relatively safe and that RNS treatment may benefit selected patients with
insular epilepsy.
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Despite multiple antiepileptic drugs (AEDs), nearly one-
third of patients still suffer from refractory epilepsy.1
Responsive neurostimulation (RNS) delivers electrical
stimulation in response to recorded electrographic seizures
in a real-time manner. It is FDA-approved as an adjunctive
therapy for adult partial-onset seizures with frequent dis-
abling seizures and no more than two seizure foci.2 Current
studies show an overall 38% seizure reduction by a 12-week
blinded follow-up. By the 1- and 2-year follow-up, there is a
44% and 53% seizure reduction, respectively.2–4 Despite
the proved overall benefit, the efficacy of neurostimulation
relative to different epileptogenic foci (e.g., temporal and
extratemporal) is unknown.
Failure to recognize insular seizures may account for sei-
zure recurrence after temporal or frontal resection sur-
gery.5,6 Insular lobe resection is difficult because of the
complicated accessibility and close proximity to eloquent
areas. However, the insula may be accessed through a depth
electrode, making patients with epilepsy originating from
the insular lobe excellent RNS candidates.
Previously, one case report described the application of
RNS targeting the insular lobe in a single patient.7 However,
relevant clinical information, including presurgical work-
up, optimal stimulation parameters, and postoperative sei-
zure outcome, is still poorly understood. In addition,
postimplantation medication adjustments have not been dis-
cussed. We report a case series of RNS application targeting
the insular cortex at a single level IV comprehensive
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epilepsy center. Our early experience may give insight into
these questions.
Methods
Patient identification and characteristics
From our patient database, we identified patients who
had undergone RNS placement with at least one electrode
placed in the insula between June 2014 and October 2015 at
the New York University (NYU) Langone Comprehensive
Epilepsy Center. All patients had inpatient scalp video elec-
troencephalograph monitoring (vEEG), a brain MRI, and
neuropsychological assessment. Invasive monitoring with
subdural grid and depth electrodes was performed in
selected patients, depending on clinical indication. All
patients were discussed in the multidisciplinary epilepsy
conference to reach consensus before proceeding with the
surgery. Intraoperative electrocorticography (ECoG) was
done in all patients to guide optimal RNS electrode place-
ment. Two patients had vagal nerve stimulation (VNS)
placement prior to RNS implantation, and VNS remained
activated during RNS treatment.
Surgical procedures
All insula RNS cases involved frameless stereotaxy
(BrainLab) that specifically targeted the insula using RNS
depth electrodes in a trajectory along the posterior to ante-
rior axis or the superior to inferior axis or some diagonal
axis rather than an orthogonal approach using a custom
depth electrode cannula system. In patients who had a his-
torical frontal resection, the insula depth electrode was
placed entering the brain from the resection margin of the
frontal resection. Bone access involved craniotomy or burr
hole depending upon the circumstances and requirements
of the RNS procedure. Whenever possible, old incisions
were used, which therefore constrained the approaches for
insula coverage. Otherwise, a posterior-to-anterior trajec-
tory via an occipital approach or a superior-to-inferior tra-
jectory via a frontal paramedical burr hole was used. The
standard RNS procedure included placement of combina-
tion of 3–4 depths and strips via craniotomy or burr hole as
well as craniectomy for the ferrule and generator assembly.
Two electrodes that demonstrated the most robust epilepti-
form discharges on intraoperative ECoG were chosen to
connect with the generator. One depth electrode was tar-
geted on the insula in this cohort. Postoperative CT imag-
ing was performed the day following the implant
(Fig. S1A,B).
Outcome assessment
Patient baseline seizure frequency was obtained from
multidisciplinary conference documents. Follow-up (6–
20 months) seizure frequency was extracted from chart
review. We report longitudinal outcome at 6-month inter-
vals in this study. Auras and simple partial sensory seizures
are not counted. A semiquantitative seizure frequency was
adapted in this study as seizure frequency reduction of more
than 75%, 50–75%, <50%, and no appreciated improve-
ment.
Results
Demographic and clinical parameters
Eight patients (3 female, 5 male) were identified. The
mean age at operation was 24 years (range 18–32). Five
patients had previous resective surgery, with resection sites
within the frontal, temporal, or insular lobes. Two patients
had multiple subpial transections (MST), and 1 patient had
an anterior corpus callosotomy in addition to resective sur-
gery (Table 1).
Electrophysiological and image findings
All patients had at least one scalp vEEG recording. One
patient’s vEEG showed a focal seizure onset over the tem-
poral region. Other patients demonstrated a nonlocalizable
seizure onset, with diffuse, bisynchronous or unilateral
broad seizure features (Table 1).
Six patients had intracranial EEG (IEEG) before the
RNS implantation. Among them, 2 patients showed a
definitive ictal onset within the insula. Three patients had
additional independent or concurrent seizure foci from two
different lobes (insular in addition to parietal, occipital, or
temporal lobe). One patient had a diffuse electrographic
onset that involved the insula. Two patients did not have
IEEG prior to RNS implantation because of elevated infec-
tion risk and adhesions from multiple prior intracranial
surgeries. Intraoperative ECoG was applied, and robust
spike discharges were noted in the insula in all patients
(Table 1).
The initial brain MRI results are summarized in Table 1.
For patients who had previous resective epilepsy surgery,
recent MRI showed postoperative changes, and therefore
original MRI images prior to the surgery were also
reviewed. In this cohort, 3 patients had normal MRI studies.
Other study results included mesial temporal sclerosis, fron-
tal atrophy, and nonspecific fluid attenuated inversion
recovery (FLAIR) signal changes (Table 1).
Postoperative complications
One patient, who also had a concurrent temporal resec-
tion at the time of RNS placement, had postoperative hydro-
cephalus that resolved after a ventriculoperitoneal shunt
placement. One patient had an intracranial infection identi-
fied 1 year after implantation that resulted in device
removal. One patient sustained damage to the device ferrule
due to head trauma, requiring replacement and lead revi-
sion. There was no clinical or radiological evidence of
intracranial hemorrhage associated with the insular elec-
trodes. No other subjects had complications from device
implantation.
Epilepsia Open, 2(3):345–349, 2017
doi: 10.1002/epi4.12061
346
H. Chen et al.
Treatment and seizure outcome
One patient reported three seizures postoperatively, and
the RNS stimulation was not turned on during the follow-up
period (19 months). The remaining 7 patients had stimula-
tion activated within 1–10 weeks postoperatively. Several
seizure onset patterns were identified in RNS ECoG record-
ing, including rhythmic theta activity (Patients 1 and 8),
burst of low-amplitude beta activity (Patient 6), as well as
rhythmic spikes of delta, theta, or alpha frequencies
(Patients 3, 4, 5, and 7). Review of recorded ECoG demon-
strated presumed seizure interruption by RNS pulse stimula-
tion in the insular cortex before further spread with some
seizures (Fig. S1C,D). The range of stimulation parameters
used varied. By the last clinic visit, the therapeutic settings
ranged from 0.5 to 3 mA (current), 160 ms (pulse width),
100 ms (burst duration), 0.5–1.5 lC/cm2 (charge density),
and 100–200 Hz (frequency). Attempts to increase stimula-
tion intensity beyond 2.5–3.5 lC/cm2 resulted in increases
in interictal activity recorded on ECoG in some patients,
and higher stimulation intensities were not used.
Patients used between two and five AEDs prior to RNS
implantation. By the last follow-up, 3 patients had a new
AED added (acetazolamide, perampanel, and clobazam).
Four patients had withdrawn previous AEDs (primidone,
eslicarbazepine, vigabatin, and zonisamide). Seven patients
had a medication dose adjustment (increase or decrease)
during the postoperative period.
Among 7 patients whose RNS were activated, 1 patient
showed reduction of seizure frequency by 75% at clinic vis-
its (last visit 20 months postoperative). Four patients
demonstrated an overall 50–75% reduction of seizures (last
visit 6–18 months, respectively). Two patients did not show
seizure improvement after RNS implantation (last visit 8
and 16 months, respectively) (Table 2). Of the 5 patients
who demonstrated ≥50% improvement, 1 also had an addi-
tion of new AEDs, and 2 patients had previous AED dose
increases following RNS implantation.
Discussion
In this retrospective case series, we describe 8 patients
who underwent implantation of the RNS system for refrac-
tory focal epilepsy that included an epileptogenic focus in
the insular cortex. The follow-up duration was 6–
20 months, and RNS devices were activated in 7 patients at
the time of last follow-up. One patient had prolonged sei-
zure freedom postoperatively, and therefore the RNS device
has not been activated at the time of last observation. A dou-
ble-blind, randomized control trial of RNS showed seizure
reduction by ~38% in the treatment group during the pivotal
phase of the clinical trial.2 In this group, patients experi-
enced a highly variable reduction in seizure frequency (no
improvement to nearly seizure free). However, 4 out of 7
(57%) patients were RNS responders (more than 50% sei-
zure reduction) by the last clinic visit. The responder rate
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was 50% (2 of 4) among patients who had 15–20 months of
follow-up. Early seizure termination by RNS treatment was
recorded in RNS ECoG. However, seizures may be refrac-
tory to RNS therapy, which can be due to insufficient stimu-
lation delivery; therefore, adjustment of therapeutic stimuli
parameters should be emphasized at each clinic visit. These
findings are overall comparable to results of a multicenter,
prospective open label study of a heterogeneous group of
patients who received RNS, which showed 44% and 55%
overall responder rate at 12 and 24 months follow-up,
respectively.3 The comparable outcome between our cohort
and previously studied patients with variable epileptogenic
foci suggests that the benefit of RNS is possibly not directly
related to implantation sites. However, further large-scale
subgroup analysis by anatomy location (such as frontal,
temporal, occipital) may further clarify this question.
Furthermore, our experience with 2 patients demonstrates
that activation of both VNS and RNS is feasible and safe.
VNS has been used as an adjunctive treatment for refractory
epilepsy, and a number of patients may have had VNS
implantation before they are referred to RNS evaluation.8 In
the pivotal study, VNS generators were explanted prior to
RNS implantation.2 In this cohort, 2 patients had a VNS
device implanted that remained active throughout the
course of RNS treatment (VNS temporarily inactivated peri-
operatively). No side effects were observed in those 2
patients.
Insular lesionectomy has achieved a satisfactory sei-
zure outcome (79% ILAE 1–3 outcome) in previous
reports.9 However, resection of the insular lobe is techni-
cally challenging and infrequently performed because of
the risk of injury of the nearby eloquent cortex and dense
vessel along the Sylvian fissure. Furthermore, resective
surgery is performed only for patients with a well-
circumscribed structural lesion, and nonlesional cases are
often excluded from the procedure.9 Because of the unfa-
vorable risk-to-benefit ratio, some patients with insular
onset seizures may be better candidates for RNS than
resective surgery.
Our case series has several limitations. The number of
patients is small, and long-term follow-up data are lacking.
The study includes a heterogeneous group of patients: 2
patients have seizures arising from the insula; while multilo-
bar (insular plus temporal, parietal, or occipital lobe) or dif-
fuse seizure onsets were identified in other patients. In
addition, 6 patients had medication adjustment (either medi-
cation switches or dose adjustment) that may also have con-
tributed to seizure reduction. One patient showed
significant seizure frequency reduction 4 months after
implantation, which temporally coincided with the addition
of new AEDs (perampanel and acetazolamide). The benefit
of AEDs should not be underestimated. A previous study of
patients with drug refractory epilepsy has shown 14%
(nearly 5% per year) obtained a 6-month terminal seizure
remission with medication adjustments over the 3 years of
follow-up.10 In addition, seizure occurrence and remission
may fluctuate during the natural course of drug-resistant
epilepsy.11 Nevertheless, from our experience, RNS
implantation within the insula is feasible and may provide
meaningful seizure reduction when the ictal onset zone is
determined from invasive monitoring. This treatment option
can be particularly applicable and should be considered for
those nonlesional cases who are not optimal candidates for
resective surgery.
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Table 2. Seizure outcome
Patient 6 months 12 months 18 months Last visit (time)
1 >75% >75% >75% >75% (at 20 months)
2a Seizure free Seizure free >75% >75% (at 19 months)
3 >75% >50% <50% <50% (at 18 months)
4b >50% >75% N/A >75% (at 15 months)
5 No improvement No improvement N/A No improvement (at 16 months)
6 >50% N/A N/A >50% (at 8 months)
7 No improvement N/A N/A No improvement (at 8 months)
8 >50% N/A N/A >50% (at 6 months)
aRNS is not activated.
bRNS is removed after the last visit.
N/A, not applicable; RNS, responsive neurostimulation.
Epilepsia Open, 2(3):345–349, 2017
doi: 10.1002/epi4.12061
348
H. Chen et al.
Journal’s position on issues involved in ethical publication and affirm that
this report is consistent with those guidelines.
References
1. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment
response in newly diagnosed epilepsy.Neurology 2012;78:1548–1554.
2. Morrell MJ, RNS System in Epilepsy Study Group. Responsive corti-
cal stimulation for the treatment of medically intractable partial epi-
lepsy.Neurology 2011;77:1295–1304.
3. Heck CN, King-Stephens D, Massey AD, et al. Two-year seizure
reduction in adults with medically intractable partial onset epilepsy
treated with responsive neurostimulation: final results of the RNS Sys-
tem Pivotal trial. Epilepsia 2014;55:432–441.
4. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with
responsive brain stimulation in adults with refractory partial seizures.
Neurology 2015;84:810–817.
5. Ryvlin P. Avoid falling into the depths of the insular trap. Epileptic
Disord 2006;S2:S37–S56.
6. Nguyen DK, Nguyen DB, Malak R, et al. Revisiting the role of the
insula in refractory partial epilepsy. Epilepsia 2009;50:510–520.
7. Smith JR, Fountas KN, Murro AM, et al. Closed-loop stimulation in
the control of focal epilepsy of insular origin. Stereotact Funct Neuro-
surg 2010;88:281–287.
8. The Vagus Nerve Stimulation Study Group. A randomized controlled
trial of chronic vagus nerve stimulation for treatment of medically
intractable seizures.Neurology 1995;45:224–230.
9. von Lehe M, Wellmer J, Urbach H, et al. Insular lesionectomy for
refractory epilepsy: management and outcome. Brain 2009;132:1048–
1056.
10. Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure
remission in an adult population with refractory epilepsy. Ann Neurol
2007;62:382–389.
11. Choi H, Heiman G, Pandis D, et al. Seizure remission and the relapse
in adults with intractable epilepsy: a cohort study. Epilepsia
2008;49:1440–1445.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. (A) Postoperative skull X-ray scan showing
cortical strip leads (temporal, frontal, parietal) and one insu-
lar depth electrode. (B) Reconstruction MRI showing the
depth electrode in the insula. (C and D) One seizure origi-
nating from the insula (channel 2 insular contact 3–4)
recorded by RNS.
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